PMID- 28663124
OWN - NLM
STAT- MEDLINE
DCOM- 20180418
LR  - 20220328
IS  - 1873-7862 (Electronic)
IS  - 0924-977X (Linking)
VI  - 27
IP  - 8
DP  - 2017 Aug
TI  - Comparative evaluation of vortioxetine as a switch therapy in patients with major 
      depressive disorder.
PG  - 773-781
LID - S0924-977X(17)30254-7 [pii]
LID - 10.1016/j.euroneuro.2017.05.009 [doi]
AB  - Switching antidepressant therapy is a recommended strategy for depressed patients 
      who neither respond to nor tolerate an initial pharmacotherapy course. This paper 
      reviews the efficacy and tolerability of switching to vortioxetine. All three 
      published studies of patients with major depressive disorder (MDD) switched from 
      SSRI/SNRI therapy to vortioxetine due to lack of efficacy or tolerability were 
      selected. Vortioxetine was evaluated versus agomelatine directly (REVIVE) and 
      versus sertraline, venlafaxine, bupropion, and citalopram in an indirect 
      treatment comparison (ITC) from switch studies retrieved in a literature review. 
      Vortioxetine׳s impact on SSRI-induced treatment-emergent sexual dysfunction 
      (TESD) was assessed directly versus escitalopram (NCT01364649) in stable patients 
      with MDD. Vortioxetine׳s tolerability in the switch population was compared to 
      the overall MDD population. Vortioxetine showed significant benefits over 
      agomelatine on efficacy, functioning, and quality-of-life outcomes, with fewer 
      withdrawals due to adverse events (AEs) (REVIVE). Vortioxetine had numerically 
      higher remission rates versus all therapies included (ITC). Withdrawal rates due 
      to AEs were significantly lower for vortioxetine versus sertraline, venlafaxine, 
      and bupropion, and numerically lower versus citalopram. Switching to vortioxetine 
      was statistically superior to escitalopram in improving TESD (NCT01364649). 
      Tolerability was similar in the switch and overall MDD populations. These 
      findings suggest that vortioxetine is an effective switch therapy for patients 
      with MDD whose response to SSRI/SNRI therapy is inadequate. Vortioxetine was well 
      tolerated and, for patients with a history of TESD, showed significant advantages 
      versus escitalopram. Vortioxetine appears to be a valid option for patients with 
      MDD who have not been effectively treated with first-line pharmacotherapies.
CI  - Copyright (c) 2017 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Thase, Michael E
AU  - Thase ME
AD  - University of Pennsylvania School of Medicine, Philadelphia, PA, USA. Electronic 
      address: thase@mail.med.upenn.edu.
FAU - Danchenko, Natalya
AU  - Danchenko N
AD  - Lundbeck SAS, Paris, France.
FAU - Brignone, Melanie
AU  - Brignone M
AD  - Lundbeck SAS, Paris, France.
FAU - Florea, Ioana
AU  - Florea I
AD  - H. Lundbeck A/S, Copenhagen, Denmark.
FAU - Diamand, Francoise
AU  - Diamand F
AD  - Lundbeck SAS, Paris, France.
FAU - Jacobsen, Paula L
AU  - Jacobsen PL
AD  - Takeda Development Center Americas, Deerfield, IL, USA.
FAU - Vieta, Eduard
AU  - Vieta E
AD  - Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, 
      Catalonia, Spain.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170627
PL  - Netherlands
TA  - Eur Neuropsychopharmacol
JT  - European neuropsychopharmacology : the journal of the European College of 
      Neuropsychopharmacology
JID - 9111390
RN  - 0 (Acetamides)
RN  - 0 (Anti-Anxiety Agents)
RN  - 0 (Piperazines)
RN  - 0 (Sulfides)
RN  - 137R1N49AD (agomelatine)
RN  - 3O2K1S3WQV (Vortioxetine)
SB  - IM
MH  - Acetamides/therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Anti-Anxiety Agents/*therapeutic use
MH  - Depressive Disorder, Major/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - *Drug Substitution
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Piperazines/*therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Sulfides/*therapeutic use
MH  - Time Factors
MH  - Vortioxetine
OTO - NOTNLM
OT  - Comparative effectiveness research
OT  - Drug switching
OT  - Drug-related side effects and adverse reactions
OT  - Major depressive disorder
OT  - Vortioxetine
EDAT- 2017/07/01 06:00
MHDA- 2018/04/19 06:00
CRDT- 2017/07/01 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/05/22 00:00 [accepted]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2018/04/19 06:00 [medline]
PHST- 2017/07/01 06:00 [entrez]
AID - S0924-977X(17)30254-7 [pii]
AID - 10.1016/j.euroneuro.2017.05.009 [doi]
PST - ppublish
SO  - Eur Neuropsychopharmacol. 2017 Aug;27(8):773-781. doi: 
      10.1016/j.euroneuro.2017.05.009. Epub 2017 Jun 27.